Fidelity Biosciences, the corporate venturing subsidiary on behalf of US-based mutual fund manager Fidelity, has participated in a $11m series B round into Kyruus, a data start-up for hospitals and health systems.
There was also involvement from Lux Capital, a venture capital firm that invests in emerging technology companies in the physical and life science, and return backers venture capital firms Venrock and Highland Capital Partners.
In conjunction with the financing, Lux Capital managing general partner Robert Paull will join the company’s board.
Graham Gardner, chief executive of Kyruus, said: “We are delighted to partner with Lux and Fidelity as we enter the next phase of our company’s growth, both firms bring important relationships with large numbers of healthcare organizations that today wrestle with how to understand and engage their physician networks. We believe our applications can transform the way these organizations coordinate physician expertise and optimize the delivery of patient care.”
To date Kyruus has raised $19.5m in venture funding. The company raised $5.5m in series A funding in June last year led by Highland Capital Partners, Venrock and strategic investor Gerson Lehrman Group, follwed by $3m in August.